Equity Details
Price & Market Data
Price: $1.65
Daily Change: -$0.089 / 5.39%
Daily Range: $1.65 - $1.79
Market Cap: $223,135,168
Daily Volume: 512,162
Performance Metrics
1 Week: -4.62%
1 Month: 3.24%
3 Months: 0.86%
6 Months: 11.78%
1 Year: -10.00%
YTD: -15.22%
About Inhibikase Therapeutics, Inc. (IKT)
Access updated market data for Inhibikase Therapeutics, Inc. (IKT). Current price: 1.65, daily change: -$0.089 / 5.39%. Market cap: 223,135,168. Performance over 1-week, 1-month, and 3-month.
Company Details
Employees: 35
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
